Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Third Quarter 2024 Results Key Financial Results Revenue: US$7.55b (up 7.0% from ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript November 6, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $2.02, expectations were $1.53. Operator: Good ...

Daina Graybosch’s rating is based on Gilead Sciences’ strong financial performance and promising pipeline developments. The company reported impressive third-quarter results, with both revenue and ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...